Doxorubicin has helped transform the treatment of many cancers, but the drug carries a dangerous biological trade-off: it can damage the heart. Now, researchers reporting in Cell Death Discovery have identified a potential way to protect cardiac muscle from this toxicity by blocking a key regulator of mitochondrial fragmentation. In their study, Deng, Bass-Stringer, Bond and colleagues examined DRP1i2, a small-molecule inhibitor of dynamin-related protein 1, or Drp1, and found that suppressing this protein reduced the chain of mitochondrial and cellular injuries associated with doxorubicin exposure.
The finding addresses one of oncology’s most persistent complications. Doxorubicin belongs to the anthracycline class of chemotherapy drugs and is used against a wide range of blood cancers and solid tumors. Its anticancer activity is linked to several mechanisms, including interference with topoisomerase II, an enzyme that manages DNA structure, and the generation of reactive oxygen species. These effects can be highly effective against rapidly dividing cancer cells, but cardiac tissue is especially vulnerable because heart muscle cells depend heavily on mitochondria to produce the energy required for continuous contraction. Unlike many other tissues, the adult heart has limited capacity to replace injured cardiomyocytes.
Mitochondria are not static structures. They constantly divide and fuse in a process known as mitochondrial dynamics, allowing cells to distribute energy-producing components, remove damaged regions and adapt to changing metabolic demands. Drp1 is a central molecular engine of mitochondrial fission. When activated, it moves from the cytosol to the mitochondrial surface, where it assembles around the organelle and constricts the membrane until one mitochondrion separates into two. Controlled fission is essential for healthy cells, but excessive or poorly regulated Drp1 activity can produce a fragmented mitochondrial network that is less efficient and more vulnerable to further damage.
The new study places this abnormal fission response at the center of doxorubicin-induced cardiotoxicity. According to the researchers, exposure to the chemotherapy drug promoted Drp1-dependent mitochondrial disruption in cardiac cells. Excessive fragmentation can impair the electron transport chain, the series of protein complexes that generates most cellular ATP through oxidative phosphorylation. At the same time, damaged mitochondria may leak more electrons, increasing the formation of reactive oxygen species. These chemically reactive molecules can attack membrane lipids, proteins and DNA, creating a self-reinforcing cycle of oxidative stress, mitochondrial failure and cell injury.
DRP1i2 was investigated as a pharmacological means of interrupting that cycle. By inhibiting Drp1 activity, the compound is designed to restrain excessive mitochondrial division without eliminating mitochondrial dynamics altogether. That distinction matters. Completely freezing fission would also interfere with normal mitochondrial quality control, including the segregation of damaged mitochondrial material for removal through mitophagy. A useful inhibitor would therefore need to reduce pathological fragmentation while preserving enough dynamic behavior for cardiac cells to maintain their organelles.
The researchers assessed whether DRP1i2 could preserve several features of cardiac-cell health after doxorubicin treatment. These types of experiments typically include measurements of mitochondrial morphology, membrane potential, oxygen consumption, cellular ATP production and the accumulation of reactive oxygen species, as well as indicators of apoptosis. The study’s central result was that DRP1i2 countered the damaging effects associated with doxorubicin, supporting the conclusion that excessive Drp1 activity is not merely a bystander effect but a therapeutically relevant part of the cardiotoxic process.
At the cellular level, protecting mitochondria may prevent the loss of cardiomyocytes before it becomes irreversible. A failing mitochondrial membrane potential limits ATP synthesis and can promote the opening of permeability pathways that trigger programmed cell death. Once apoptosis is activated, cardiomyocytes can be lost through a process involving mitochondrial release of pro-death factors, caspase activation and fragmentation of cellular DNA. By stabilizing mitochondrial function, Drp1 inhibition could reduce the biochemical signals that push stressed heart cells toward apoptosis. This mechanism is particularly important because cumulative injury may remain clinically silent for years before emerging as reduced cardiac contractility.
The work also highlights why cardiotoxicity is difficult to solve with a single antioxidant. Reactive oxygen species are part of the damage caused by doxorubicin, but they are also products of broader mitochondrial and metabolic disturbances. Simply neutralizing oxidants may not correct the structural defects that allow dysfunctional mitochondria to accumulate. Targeting Drp1 addresses an upstream process: the physical remodeling of mitochondria that can intensify oxidative stress, disrupt energy production and activate cell-death pathways. The approach therefore represents a shift from treating one chemical consequence of doxorubicin exposure to modifying the organelle-level response that helps generate several consequences at once.
The findings remain a preclinical advance rather than a ready-to-use treatment for patients receiving chemotherapy. A cardioprotective drug would need to shield the heart without weakening doxorubicin’s ability to kill tumor cells. That question is central to future studies, because mitochondrial fission and Drp1 signaling can also influence the survival, metabolism and stress responses of cancer cells. Researchers will need to determine the appropriate dose and timing of DRP1i2, establish how long its protective effects last, and test whether it interacts with doxorubicin’s anticancer activity in different tumor types. Animal studies and, eventually, carefully designed clinical trials will also be required to examine pharmacokinetics, toxicity and effects on heart function over both short and long periods.
Even with those questions unresolved, the study offers a compelling molecular explanation for how a widely used chemotherapy can injure the heart and identifies Drp1 inhibition as a possible countermeasure. The broader significance extends beyond doxorubicin: excessive mitochondrial fission has been implicated in ischemia-reperfusion injury, neurodegeneration, metabolic disease and other disorders in which cellular energy systems collapse under stress. DRP1i2 may therefore serve not only as a candidate cardioprotective compound but also as a tool for testing how mitochondrial architecture governs disease. For cancer medicine, the immediate promise is clear—protecting the heart could allow patients to receive life-saving anthracycline therapy with fewer long-term cardiac consequences, provided future research confirms that mitochondrial protection can be achieved without compromising cancer treatment.
Subject of Research: Cardioprotection against doxorubicin-induced cardiotoxicity through inhibition of Drp1-mediated mitochondrial fission
Article Title: The Drp1 inhibitor DRP1i2 confers cardioprotection against doxorubicin-induced cardiotoxicity
Article References: Deng, Y., Bass-Stringer, S.T., Bond, S.T. et al. “The Drp1 inhibitor DRP1i2 confers cardioprotection against doxorubicin-induced cardiotoxicity.” Cell Death Discovery (2026). https://doi.org/10.1038/s41420-026-03311-8
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41420-026-03311-8
Keywords: Doxorubicin, cardiotoxicity, Drp1, DRP1i2, mitochondrial fission, mitochondrial dynamics, cardioprotection, oxidative stress, apoptosis, cancer therapy
